慢性HBV感染免疫耐受期抗病毒治疗有益于预防肝硬化和肝癌的发生

贾红宇; 刘克洲

doi:10.3969/j.issn.1001-5256.2021.05.007

慢性HBV感染免疫耐受期抗病毒治疗有益于预防肝硬化和肝癌的发生

DOI: 10.3969/j.issn.1001-5256.2021.05.007

贾红宇,
刘克洲^,

浙江大学医学院附属第一医院感染病科，传染病国家重点实验室，杭州 310003

详细信息

作者简介:
贾红宇(1974—)，副主任医师，博士，主要从事病毒性肝炎治疗的研究

通信作者:
刘克洲，liukezhou@zju.edu.cn

中图分类号: R512.62
计量
- 文章访问数: 266
- HTML全文浏览量: 91
- PDF下载量: 76
- 被引次数: 0
出版历程
- 收稿日期: 2021-03-22
- 录用日期: 2021-03-29
- 出版日期: 2021-05-20

Antiviral therapy for patients in the immune-tolerant phase of chronic HBV infection is beneficial for preventing liver cirrhosis and hepatocellular carcinoma

Hongyu JIA,
Kezhou LIU^,

State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Department of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China

摘要

- 乙型肝炎病毒 /
- 乙型肝炎, 慢性 /
- 免疫耐受 /
- 治疗学
- Hepatitis B Virus /
- Hepatitis B, Chronic /
- Immune Tolerance /
- Therapeutics

HTML全文

参考文献(17)

[1]	TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800.
[2]	European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021.
[3]	SARIN SK, KUMAR M, LAU GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update[J]. Hepatol Int, 2016, 10(1): 1-98. DOI: 10.1007/s12072-015-9675-4.
[4]	Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[5]	LIANG XE, SUN J. Assessing the relationship between ALT level with disease progression and treatment timing[J]. Chin J Hepatol, 2020, 28(12): 992-994. DOI: 10.3760/cma.j.cn501113- 20201022-00571. 梁携儿, 孙剑. 如何评价ALT水平与疾病进展及治疗时机的关系[J]. 中华肝脏病杂志, 2020, 28(12): 992-994. DOI: 10.3760/cma.j.cn501113-20201022-00571.
[6]	National Health Commission of the people's Republic of China. Reference intervals for common clinical biochemistry tests-part 1[EB/OL]. (2012-12-25)[2021-03-22].http://www.nhc.gov.cn/wjw/s9492/201301/9b2e494990ce4825a48b4b476f6f928b.shtml. 中华人民共和国国家卫生健康委员会. 临床常用生化检验项目参考区间第1部分[EB/OL]. (2012-12-25)[2021-03-22]. http://www.nhc.gov.cn/wjw/s9492/201301/9b2e494990ce4825a48b4b476f6f928b.shtml.
[7]	LESMANA CR, GANI RA, HASAN I, et al. Significant hepatic histopathology in chronic hepatitis B patients with serum ALT less than twice ULN and high HBV-DNA levels in Indonesia[J]. J Dig Dis, 2011, 12(6): 476-480. DOI: 10.1111/j.1751-2980.2011.00540.x.
[8]	PARK JY, PARK YN, KIM DY, et al. High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels[J]. J Viral Hepat, 2008, 15(8): 615-621. DOI: 10.1111/j.1365-2893.2008.00989.x.
[9]	GÖBEL T, ERHARDT A, HERWIG M, et al. High prevalence of significant liver fibrosis and cirrhosis in chronic hepatitis B patients with normal ALT in central Europe[J]. J Med Virol, 2011, 83(6): 968-973. DOI: 10.1002/jmv.22048.
[10]	MASON WS, GILL US, LITWIN S, et al. HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant[J]. Gastroenterology, 2016, 151(5): 986-998. e4. DOI: 10.1053/j.gastro.2016.07.012.
[11]	KIM GA, LIM YS, HAN S, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B[J]. Gut, 2018, 67(5): 945-952. DOI: 10.1136/gutjnl-2017-314904.
[12]	ZHU S, ZHANG H, DONG Y, et al. Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: A pilot open-label randomized study[J]. J Hepatol, 2018, 68(6): 1123-1128. DOI: 10.1016/j.jhep.2018.01.037.
[13]	PODDAR U, YACHHA SK, AGARWAL J, et al. Cure for immune-tolerant hepatitis B in children: Is it an achievable target with sequential combo therapy with lamivudine and interferon?[J]. J Viral Hepat, 2013, 20(5): 311-316. DOI: 10.1111/jvh.12007.
[14]	KIM HL, KIM GA, PARK JA, et al. Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B[J]. Gut, 2020. DOI: 10.1136/gutjnl-2020-321309.[Online ahead of print]
[15]	Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3(6): 383-403. DOI: 10.1016/S2468-1253(18)30056-6.
[16]	Bureau of Disease Prevention and Control, Ministry of Health, Chinese Center for Disease Control and Prevention. Investigation Report on Serological Epidemiology of the Hepatitis B Virus Among the National Population in China[M]. Beijing: People's Medical Publishing House, 2011: 29. 卫生部疾病预防控制局, 中国疾病预防控制中心. 全国人群乙型病毒性肝炎血清流行病学调查报告[M]. 北京: 人民卫生出版社, 2011: 29.
[17]	JENG WJ, LOK AS. Should treatment indications for chronic hepatitis B be expanded?[J]. Clin Gastroenterol Hepatol, 2020. DOI: 10.1016/j.cgh.2020.04.091.[Online ahead of print]